![]() Please Wait... |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Protocol OverviewBrowse » Domains » Skin, Bone, Muscle and Joint » Personal and Family History of Psoriasis » Personal and Family History of Psoriasis Note: Some Protocols contain images. You may click the thumbnails to preview the full image. To print Protocols with full size images, please add those Protocols to your Toolkit and Generate a Report.
Personal and Family History of Psoriasis #170501
Protocol Release Date
![]() ![]() November 12, 2010 Protocol Name From Source
![]() ![]() The Expert Review Panel has not reviewed this measure yet. Description of Protocol
![]() ![]() The Self Evaluation plus Medication Survey is a self-administered instrument which was developed from the questionnaires used in the Collaborative Association Study of Psoriasis (CASP), which is a Genetic Association Information Network (GAIN) genome-wide association study (GWAS). The Self Evaluation plus Medication Survey collects information on individuals with psoriasis and controls, and their family history of psoriasis and other autoimmune diseases. Additionally, for individuals with psoriasis the questionnaire collects information regarding their symptoms and medication use and its effectiveness. Specific Instructions
![]() ![]() The PhenX Skin, Bone, Muscle and Joint Working Group (WG) recommends that investigators provide participants with an informed consent form which allows future contact for physician validation of their diagnosis and to update information on their health status. Immediately following the alcohol and tobacco questions, the Self Evaluation plus Medication Survey asked questions regarding the respondent’s weight and height. These questions have been deleted. The Working Group recommends that this information be obtained via the PhenX measures titled Weight and Height, respectively. These measures are located in the PhenX Toolkit, under the Anthropometrics domain. Protocol
![]() ![]() Psoriasis Self Evaluation plus Medication Survey If affected with psoriasis: 1. Age at which symptoms appeared: _______ 2. Age at which psoriasis was diagnosed by a physician: _______ 3. Is the physician who diagnosed you a dermatologist: [ ] Yes [ ] No Name of your current dermatologist: _________________________________________ 4. If affected with arthritis: 4a. Age at which symptoms appeared: _______ 4b. Age at which arthritis was diagnosed by a physician: _______ 4c. Have you been told by a rheumatologist that you have psoriatic arthritis? [ ] Yes [ ] No 5. Have you been diagnosed with Crohn’s disease or another inflammatory bowel disorder? [ ] Yes [ ] No [ ] Explanation:____________________________________________________ 6. Have you been diagnosed with any type of autoimmune disease (lupus, scleroderma, etc.)? [ ] Yes [ ] No [ ] Explanation:____________________________________________________ 7. Do you have any blood relatives affected with psoriasis? [ ] Yes [ ] No 7a. If yes, relationship(s) ___________________________________________ ____________________________________________________________________________ 8. Do you have any blood relatives with inflammatory bowel disease? [ ] Yes [ ] No [ ] Explanation:_____________________________________________________ 9. Do you have any blood relatives with any type of autoimmune disease? [ ] Yes [ ] No [ ] Explanation:_____________________________________________________ STOP HERE IF YOU ARE PARTICIPATING AS A CONTROL AND DO NOT HAVE PSORIASIS. 10. How bad is your psoriasis today? Please answer each of the following three questions by placing an X mark anywhere on the line to show how red, thick, and scaly an average spot of your psoriasis is. 10A. What color is an average spot of your psoriasis? No redness Slight pink Pink Red Dark red
10B. How thick is an average spot of your psoriasis? No thickness Feels firm Raised Thick Very thick
10C. How scaly is an average spot of your psoriasis? No scale Slight scale Scaly Flaky Very flaky
10D. Has a dermatologist told you that you have pustular psoriasis? [ ] Yes [ ] No 10E. Do you have nail psoriasis (pitting of nail surface, thickened or crumbly nails, excessive separation of the tips of the nails from the nail bed, or yellow-orange spotting of the nails)? [ ] Yes [ ] No 10e1.If yes, number of fingernails affected _______; number of toenails affected ________. 11. On the drawings below, mark areas of your body affected with psoriasis NOW. Please also write any explanation you wish to add below the drawings.
12. On the drawings below, mark areas of your body affected with psoriasis WHEN IT WAS THE WORST IT HAS EVER BEEN. Again, feel free to write any explanation you wish to add below the drawings.
Psoriasis Medication Usage and Effectiveness History Alcohol and tobacco usage 13. How many of the following do you smoke per day? [ ] Cigarettes ______ [ ] Cigars ______ [ ] Pipes ______ 14. How many alcoholic drinks do you have per week _________ (one drink = one beer = one glass of wine = one cocktail) Please mark any of the following medications you are using or have used in the past as appropriate. Topical medications (creams, lotions etc.) 15. Dovonex® Usage duration: ____ years ____months Effectiveness on 0–5 scale (0 = not effective, 5 = very effective), please circle one: 0 [ ] not effective 1 [ ] 2 [ ] 3 [ ] 4 [ ] 5 [ ] very effective Comments:_______________________________________________________________________ ________________________________________________________________________________ 16. Anthralin Usage duration: ____ years ____months Effectiveness on 0–5 scale (0 = not effective, 5 = very effective), please circle one: 0 [ ] not effective 1 [ ] 2 [ ] 3 [ ] 4 [ ] 5 [ ] very effective Comments:_______________________________________________________________________ ________________________________________________________________________________ 17. Coal Tar Usage duration: ____ years ____months Effectiveness on 0–5 scale (0 = not effective, 5 = very effective), please circle one: 0 [ ] not effective 1 [ ] 2 [ ] 3 [ ] 4 [ ] 5 [ ] very effective Comments:_______________________________________________________________________ ________________________________________________________________________________ 18. Other, please describe: __________________________________________________ Usage duration: ____ years ____months Effectiveness on 0–5 scale (0 = not effective, 5 = very effective), please circle one: 0 [ ] not effective 1 [ ] 2 [ ] 3 [ ] 4 [ ] 5 [ ] very effective Comments:_______________________________________________________________________ ________________________________________________________________________________ 19. Other, please describe: __________________________________________________ Usage duration: ____ years ____months Effectiveness on 0–5 scale (0 = not effective, 5 = very effective), please circle one: 0 [ ] not effective 1 [ ] 2 [ ] 3 [ ] 4 [ ] 5 [ ] very effective Comments:_______________________________________________________________________ ________________________________________________________________________________ Systemic medications (oral medications) 20. Methotrexate Usage duration: ____ years ____months Effectiveness on 0–5 scale (0 = not effective, 5 = very effective), please circle one: 0 [ ] not effective 1 [ ] 2 [ ] 3 [ ] 4 [ ] 5 [ ] very effective Comments:_______________________________________________________________________ ________________________________________________________________________________ 21. Soriatane® Usage duration: ____ years ____months Effectiveness on 0–5 scale (0 = not effective, 5 = very effective), please circle one: 0 [ ] not effective 1 [ ] 2 [ ] 3 [ ] 4 [ ] 5 [ ] very effective Comments:_______________________________________________________________________ ________________________________________________________________________________ 22. Cyclosporine Usage duration: ____ years ____months Effectiveness on 0–5 scale (0 = not effective, 5 = very effective), please circle one: 0 [ ] not effective 1 [ ] 2 [ ] 3 [ ] 4 [ ] 5 [ ] very effective Comments:_______________________________________________________________________ ________________________________________________________________________________ 23. Other, please describe: __________________________________________________ Usage duration: ____ years ____months Effectiveness on 0–5 scale (0 = not effective, 5 = very effective), please circle one: 0 [ ] not effective 1 [ ] 2 [ ] 3 [ ] 4 [ ] 5 [ ] very effective Comments:_______________________________________________________________________ ________________________________________________________________________________
Biologicals (injected) 24. Enbrel® Usage duration: ____ years ____months Effectiveness on 0–5 scale (0 = not effective, 5 = very effective), please circle one: 0 [ ] not effective 1 [ ] 2 [ ] 3 [ ] 4 [ ] 5 [ ] very effective 25. Humira™ Usage duration: ____ years ____months Effectiveness on 0–5 scale (0 = not effective, 5 = very effective), please circle one: 0 [ ] not effective 1 [ ] 2 [ ] 3 [ ] 4 [ ] 5 [ ] very effective 26. Raptiva™ Usage duration: ____ years ____months Effectiveness on 0–5 scale (0 = not effective, 5 = very effective), please circle one: 0 [ ] not effective 1 [ ] 2 [ ] 3 [ ] 4 [ ] 5 [ ] very effective 27. Amevive® Usage duration: ____ years ____months Effectiveness on 0–5 scale (0 = not effective, 5 = very effective), please circle one: 0 [ ] not effective 1 [ ] 2 [ ] 3 [ ] 4 [ ] 5 [ ] very effective 28. Remicade® Usage duration: ____ years ____months Effectiveness on 0–5 scale (0 = not effective, 5 = very effective), please circle one: 0 [ ] not effective 1 [ ] 2 [ ] 3 [ ] 4 [ ] 5 [ ] very effective 29. Other, please describe: __________________________________________________ Usage duration: ____ years ____months Effectiveness on 0–5 scale (0 = not effective, 5 = very effective), please circle one: 0 [ ] not effective 1 [ ] 2 [ ] 3 [ ] 4 [ ] 5 [ ] very effective Comments on any/all biologicals:_____________________________________________________ ________________________________________________________________________________ Phototherapy 30. PUVA Usage duration: ____ years ____months Effectiveness on 0–5 scale (0 = not effective, 5 = very effective), please circle one: 0 [ ] not effective 1 [ ] 2 [ ] 3 [ ] 4 [ ] 5 [ ] very effective Comments:_______________________________________________________________________ ________________________________________________________________________________ 31. UVB Usage duration: ____ years ____months Effectiveness on 0–5 scale (0 = not effective, 5 = very effective), please circle one: 0 [ ] not effective 1 [ ] 2 [ ] 3 [ ] 4 [ ] 5 [ ] very effective Comments:_______________________________________________________________________ ________________________________________________________________________________ Dovonex® a registered trademark, LEO PHARMA A/S Corporation Denmark No.55 Industriparken Ballerup Denmark DK-2750; Soriatane® a registered trademark, Stiefel Laboratories, Inc.; Enbrel® a registered trademark, Immunex Corporation; Humira ™ a registered trademark, Abbott Laboratories; Raptiva™ a registered trademark, Genentech Inc.; Amevive® a registered trademark, Astellas US LLC; Remicade® a registered trademark, Centocor Ortho Biotech Inc. Variables ![]() ![]()
Selection Rationale
![]() ![]() Although there are various psoriasis instruments, the Self Evaluation plus Medication Survey was selected by the PhenX Skin, Bone, Muscle and Joint Working Group because of its development from the Collaborative Association Study of Psoriasis (CASP), its application for individuals with psoriasis and controls, and its ability to obtain information on the presence of specific diseases within their family. Source
![]() ![]() The Self Evaluation plus Medication Survey was provided by the Psoriasis Genetics Laboratory, Department of Dermatology, University of Michigan Medical School, Ann Arbor, MI. Of note, the questions in this survey have been renumbered 1–31. Life Stage
![]() ![]() Adult, Senior Language
![]() ![]() English Participant
![]() ![]() Adults, older adults Personnel and Training Required
![]() ![]() None Equipment Needs
![]() ![]() The respondent will need a copy of the questionnaire. Standards
![]() ![]()
General References
![]() ![]() Nair, R. P., Stuart, P. E., Nistor, I., Hiremagalore, R., Chia, N. V. C., Jenisch, S., Weichenthal, M., Abeasis, G. R., Lim, H. W., Christophers, E., Voorhees, J. J., & Elder, J. T. (2006). Sequence and haplotype analysis supports HLA-C as the Psoriasis Susceptibility 1 gene. American Journal of Human Genetics, 78, 827–851. PMCID: PMC1474031. Nair, R. P., Ruether, A., Stuart, P. E., Jenisch, S., Tejasvi, T., Hiremagalore, R., Schreiber, S., Kabelitz, D., Lim, H. W., Voorhees, J. J., Christophers, E., Elder, J. T., & Weichenthal, M. (2008). Polymorphisms of the IL12B and IL23R genes are associated with psoriasis. Journal of Investigative Dermatology, 128, 1653–1661. PMCID: PMC2739284. Nair, R. P., Callis Duffin, K., Helms, C., Ding, J., Stuart, P. E., Goldgar, D., Gudjonsson, J., Li, Y., Tejasvi, T., Feng, B. J., Ruether, A., Schreiber, S., Weichenthal, M., Gladman, D., Rahman, P., Schrodi, S. J., Prahalad, S., Guthery, S. L., Fischer, J., Liao, W., Kwok, P., Menter, A., Lathrop, G. M., Wise, C., Begovich, A. B., Voorhees, J. J., Elder, J. T., Krueger, G. G., Bowcock, A. M., & Abecasis, G. R. (2009). Genome-wide scan of psoriasis reveals association with IL-23 and NF-kB pathways. Nature Genetics, 41(2), 199–204. PMCID: PMC2745122. de Cid, R., Riveira-Munoz, E., Zeeuwen, P. L. J. M., Robarge, J., Liao, W., Dannhauser, E. N., Giardina, E., Stuart, P. E., Nair, R. P., Helms, C., Escarams, G., Ballana, E., Martn-Ezquerra, G., den Heijer, M., Kamsteeg, M., Joosten, I., Eichler, E. E., Lzaro, C., Pujol, R. M., Armengol, L., Abecasis, G., Elder, J. T., Novelli, G., Armour, J. A. L., Kwok, P., Bowcock, A., Schalkwijk, J., & Estivill, X. (2009). Deletion of the late cornified envelope (LCE) 3B and 3C genes as a susceptibility factor for psoriasis. Nature Genetics, 41(2), 211-215. NIHMSID: NIHMS213228. Stuart, P. E., Nair, R. P., Hiremagalore, R., Kullavanijaya, P., Kullavanijaya, P., Tejasvi, T., Lim, H. W., Voorhees, J. J., & Elder, J. T. (2010). Comparison of MHC Class I risk haplotypes in Thai and Caucasian psoriatics reveals locus heterogeneity at PSORS1. Tissue Antigens, July 1 [E-pub ahead of print]. NIHMSID: NIHMS215411 Stuart, P. E., Nair, R. P., Ellinghaus, E., Ding, J., Tejasvi, T., Gudjonsson, J. E., Li, Y., Weidinger, S., Eberlein, B., Gieger, C., Wichmann, H. E., Kunz, M., Ike, R., Mroweitz, U., Lim, H. W., Voorhees, J. J., Abecasis, G. R., Weichenthal, M., Franke, A., Rahman, P., Gladman, D., & Elder, J. T. (in press). Genome-wide association analysis identifies three psoriasis susceptibility loci. Nature Genetics. Mode of Administration
![]() ![]() Self-administered questionnaire Derived Variables
![]() ![]() None Requirements
![]() ![]()
Process and Review
![]() ![]() The Expert Review Panel has not reviewed this measure yet. Please cite use of the PhenX Toolkit as: http://www.phenxtoolkit.org - April 11, 2017, Ver 21.0 |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Site maintained by RTI International
Home | Browse | Search | My Toolkit | Feedback
Release: April 11, 2017, Ver 21.0
|

Please Wait...


Add this protocol to My Toolkit